Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Ocaperidone

From Wikipedia, the free encyclopedia
Ocaperidone
Names
Preferred IUPAC name
3-{2-[4-(6-Fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one
Identifiers
3D model (JSmol)
ChemSpider
KEGG
MeSHC072259
UNII
  • InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3
    Key: ZZQNEJILGNNOEP-UHFFFAOYSA-N
  • InChI=1/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3
    Key: ZZQNEJILGNNOEP-UHFFFAOYAT
  • CC1=CC=CN2C1=NC(=C(C2=O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F)C
Properties
C24H25FN4O2
Molar mass420.488 g·mol−1
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa).
Chemical compound

Ocaperidone (R 79598) is abenzisoxazoleantipsychotic.[1] It was initially developed byJanssen, later licensed to French laboratory Neuro3D and then acquired in 2007 by German companyEvotec. It was found to be more potent thanrisperidone in animal studies,[2] but its testing was abandoned in 2010 after unfavorable results in human Phase II trials,[3] as while it was effective at controlling symptoms ofschizophrenia, ocaperidone produced an unacceptable amount ofextrapyramidal side effects.[4]

Synthesis

[edit]

The last step requires attachment of the sidechain between 3-(2-bromoethyl)-2,9-dimethyl 4H-pyrido[1,2-a]pyrimidin-4-one (1) and 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole (2) completing theconvergent synthesis of ocaperidone (3).

Patented method for the synthesis of ocaperidone[5]

See also

[edit]

References

[edit]
  1. ^Leysen, JE; Janssen, PM; Gommeren, W; Wynants, J; Pauwels, PJ; Janssen, PA (1992). "In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone".Molecular Pharmacology.41 (3):494–508.PMID 1372084.
  2. ^Megens, AA; Awouters, FH; Meert, TF; Schellekens, KH; Niemegeers, CJ; Janssen, PA (Jan 1992). "Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598)".J Pharmacol Exp Ther.260 (1):146–59.PMID 1370538.
  3. ^"Ocaperidone — AdisInsight".Adis Insight. Adis International Ltd, part of Springer Science+Business Media. Retrieved10 December 2015.
  4. ^Geerts, Hugo; Spiros, Athan; Roberts, Patrick; Twyman, Roy; Alphs, Larry; Grace, Anthony A. (2012)."Blinded Prospective Evaluation of Computer-Based Mechanistic Schizophrenia Disease Model for Predicting Drug Response".PLOS ONE.7 (12) e49732.Bibcode:2012PLoSO...749732G.doi:10.1371/journal.pone.0049732.PMC 3522663.PMID 23251349.
  5. ^Ludo E. J. Kennis, Jan Vandenberk, & Albertus H. M. T. Van Heertum,U.S. patent 5,482,943 (1996 to Janssen Pharmaceutica NV).


Typical
Disputed
Atypical
Others
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
H1
Agonists
Antagonists
H2
Agonists
Antagonists
H3
Agonists
Antagonists
H4
Agonists
Antagonists
5-HT1
5-HT1A
5-HT1B
5-HT1D
5-HT1E
5-HT1F
5-HT2
5-HT2A
5-HT2B
5-HT2C
5-HT37
5-HT3
5-HT4
5-HT5A
5-HT6
5-HT7
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ocaperidone&oldid=1316392563"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp